These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
285 related articles for article (PubMed ID: 8106165)
41. Effects of carvedilol on plasma levels of pro-inflammatory cytokines in patients with ischemic and nonischemic dilated cardiomyopathy. Kurum T; Tatli E; Yuksel M Tex Heart Inst J; 2007; 34(1):52-9. PubMed ID: 17420794 [TBL] [Abstract][Full Text] [Related]
42. Carvedilol reverses elevated pulmonary vascular resistance in a child with dilated cardiomyopathy. Horenstein MS; Ross RD; Singh TP; Epstein ML Pediatr Cardiol; 2002; 23(1):100-2. PubMed ID: 11922497 [TBL] [Abstract][Full Text] [Related]
43. Carvedilol prospective randomized cumulative survival (COPERNICUS) trial: carvedilol in severe heart failure. Fowler MB Am J Cardiol; 2004 May; 93(9A):35B-9B. PubMed ID: 15144935 [TBL] [Abstract][Full Text] [Related]
44. Carvedilol in the treatment of chronic heart failure: lessons from the Carvedilol Or Metoprolol European Trial. Kveiborg B; Major-Petersen A; Christiansen B; Torp-Pedersen C Vasc Health Risk Manag; 2007; 3(1):31-7. PubMed ID: 17583173 [TBL] [Abstract][Full Text] [Related]
45. Influence of beta-blockers on mortality in chronic heart failure. Hart SM Ann Pharmacother; 2000 Dec; 34(12):1440-51. PubMed ID: 11144703 [TBL] [Abstract][Full Text] [Related]
46. Carvedilol produces sustained long-term benefits: follow-up at 12 years. MacGregor JF; Wachter SB; Munger M; Stoddard G; Bristow MR; Gilbert EM Congest Heart Fail; 2009; 15(1):5-8. PubMed ID: 19187400 [TBL] [Abstract][Full Text] [Related]
47. A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. Botoni FA; Poole-Wilson PA; Ribeiro AL; Okonko DO; Oliveira BM; Pinto AS; Teixeira MM; Teixeira AL; Reis AM; Dantas JB; Ferreira CS; Tavares WC; Rocha MO Am Heart J; 2007 Apr; 153(4):544.e1-8. PubMed ID: 17383291 [TBL] [Abstract][Full Text] [Related]
48. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026 [TBL] [Abstract][Full Text] [Related]
50. Second- and third-generation beta-blocking drugs in chronic heart failure. Bristow MR; Abraham WT; Yoshikawa T; White M; Hattler BG; Crisman TS; Lowes BD; Robertson AD; Larrabee P; Gilbert EM Cardiovasc Drugs Ther; 1997 May; 11 Suppl 1():291-6. PubMed ID: 9211023 [TBL] [Abstract][Full Text] [Related]
51. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). Remme WJ; Riegger G; Hildebrandt P; Komajda M; Jaarsma W; Bobbio M; Soler-Soler J; Scherhag A; Lutiger B; Rydén L Cardiovasc Drugs Ther; 2004 Jan; 18(1):57-66. PubMed ID: 15115904 [TBL] [Abstract][Full Text] [Related]
52. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. Gattis WA; O'Connor CM; Gallup DS; Hasselblad V; Gheorghiade M; J Am Coll Cardiol; 2004 May; 43(9):1534-41. PubMed ID: 15120808 [TBL] [Abstract][Full Text] [Related]
53. Carvedilol for heart failure: more than just a beta-blocker? Cleland JG Br J Hosp Med; 1997 Nov 19-Dec 9; 58(10):493-7. PubMed ID: 10193451 [TBL] [Abstract][Full Text] [Related]
54. Effects of carvedilol on cardiac function and cardiac adrenergic neuronal damage in rats with dilated cardiomyopathy. Watanabe K; Takahashi T; Nakazawa M; Wahed MI; Fuse K; Tanabe N; Kodama M; Aizawa Y; Ashino H; Tazawa S J Nucl Med; 2002 Apr; 43(4):531-5. PubMed ID: 11937598 [TBL] [Abstract][Full Text] [Related]
55. The effects of intravenous carvedilol, a new multiple action vasodilatory beta-blocker, in congestive heart failure. DasGupta P; Broadhurst P; Lahiri A J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S12-6. PubMed ID: 1721973 [TBL] [Abstract][Full Text] [Related]
56. [Congestive heart failure and acute myocardial infarction: latest trials with beta-blocking agents]. Isnard R Ann Cardiol Angeiol (Paris); 2002 Jan; 51(1):48-50. PubMed ID: 12510669 [No Abstract] [Full Text] [Related]
57. Myocardial beta-adrenergic receptor density assessed by 11C-CGP12177 PET predicts improvement of cardiac function after carvedilol treatment in patients with idiopathic dilated cardiomyopathy. Naya M; Tsukamoto T; Morita K; Katoh C; Nishijima K; Komatsu H; Yamada S; Kuge Y; Tamaki N; Tsutsui H J Nucl Med; 2009 Feb; 50(2):220-5. PubMed ID: 19164238 [TBL] [Abstract][Full Text] [Related]
58. Treatment of dilated cardiomyopathy with carvedilol in children. Erdoğan I; Ozer S; Karagöz T; Celiker A; Ozkutlu S; Alehan D Turk J Pediatr; 2009; 51(4):354-60. PubMed ID: 19950843 [TBL] [Abstract][Full Text] [Related]
59. The role of third-generation beta-blocking agents in chronic heart failure. Bristow MR; Roden RL; Lowes BD; Gilbert EM; Eichhorn EJ Clin Cardiol; 1998 Dec; 21(12 Suppl 1):I3-13. PubMed ID: 9853189 [TBL] [Abstract][Full Text] [Related]